We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

MINDRAY In-Vitro Diagnostics

As a global leader in in-vitro diagnostics, Mindray provides a wide range of efficient, reliable IVD solutions for la... read more Featured Products: More products

Download Mobile App




Hematology Analyzer Screens for Malaria in Clinical Setting

By LabMedica International staff writers
Posted on 14 Aug 2019
Print article
Image: The BC-6800 benchtop automatic hematology analyzer (Photo courtesy of Mindray).
Image: The BC-6800 benchtop automatic hematology analyzer (Photo courtesy of Mindray).
Malaria is a vector-borne infectious disease that continues to have high morbidity and mortality globally. Diagnosis based only on clinical symptoms has very low specificity as there is no combination of symptoms that reliably distinguishes malaria from other causes of fever or influenza.

Light microscopy, malaria nucleic acid amplification (PCR) test and malaria rapid diagnostic tests (RDTs) are used for parasitological diagnosis of malaria. Malaria PCR is not commonly used due to its high cost; RDTs are now more common, but not yet the regular test in non-endemic areas and microscopic examination of stained blood films remains the standard.

Clinical Laboratory Scientists from the Chinese People’s Liberation Army General Hospital (Beijing, China) collected a total of 181 samples, including 117 malaria-infected samples collected from Yunnan, China, and 64 samples from healthy controls. Microscopy examination was conducted as reference when stained thick blood film revealed the presence of malaria parasites identified as Plasmodium vivax and P. falciparum.

The team examined all blood samples using both light microscopy and the BC-6800 hematology analyzer. The BC-6800 hematology analyzer used sheath flow impedance, laser scatter and SF Cube analysis technology. In the BC-6800 differentiating (DIFF) channel, the fluorescent staining technology was adopted after the sample was mixed with DIFF lyse. For samples infected with malaria, RBC and white blood cell (WBC) sub-populations were differentiated by their size and complexity using lysing. The DIFF channel differentiates the sub-populations, including lymphocytes, monocytes, neutrophils, Plasmodium-infected RBC, and eosinophils, as well as identifies and flags abnormal cells such as immature granulocytes, abnormal lymphocytes and blast cells.

The BC-6800 hematology analyzer provides a dedicated flag ‘Infected RBC’ (InR) and the number of InR (InR#)/the permillage of InR (InR‰) in routine blood testing as a screening tool for malaria in endemic areas. The authors reported that the sensitivity of InR‰ generated by the BC-6800 for P. vivax and P. falciparum was 88.3% and 24.1%, respectively; specificity of InR‰ for malaria parasites was 84.3% and 84.3%, respectively; positive predictive value and negative predictive value was 89.4% and 82.7% for P. vivax, and 52.8% and 60.3% for P. falciparum. There was a strong correlation between the change in the differential WBCs and InR‰. There was also a significant correlation between parasitaemia and InR# in P. vivax-infected samples.

The authors concluded that their findings suggest that the flag ‘InR’ and the parameters ‘InR#/InR‰’ provided by the BC-6800 hematology analyzer could be used in malaria-endemic zones, ‘Infected RBC’ flag could serve as a rapid decision support tool when screening for malaria. The study was published on July 31, 2019, in the Malaria Journal.

Related Links:
Chinese People’s Liberation Army General Hospital

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Unstirred Waterbath
HumAqua 5
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.